Is there potential for the approval of monoclonal antibodies to treat thyroid-associated ophthalmopathy?
作者信息
Smith Terry J
机构信息
University of Michigan Ringgold standard institution - Ophthalmology and Visual Sciences, Ann Arbor, Michigan, USA.
出版信息
Expert Opin Orphan Drugs. 2018;6(10):593-595. doi: 10.1080/21678707.2018.1521268. Epub 2018 Sep 26.
Abstract
摘要
相似文献
1
Is there potential for the approval of monoclonal antibodies to treat thyroid-associated ophthalmopathy?单克隆抗体用于治疗甲状腺相关性眼病有获批的可能性吗？
Expert Opin Orphan Drugs. 2018;6(10):593-595. doi: 10.1080/21678707.2018.1521268. Epub 2018 Sep 26.
2
Ability of monoclonal antibodies to the thyrotropin receptor to increase collagen synthesis in human fibroblasts: an assay which appears to measure exophthalmogenic immunoglobulins in Graves' sera.抗促甲状腺素受体单克隆抗体增加人成纤维细胞胶原蛋白合成的能力：一种似乎可检测格雷夫斯病血清中致突眼免疫球蛋白的测定方法。
J Clin Endocrinol Metab. 1986 Feb;62(2):357-67. doi: 10.1210/jcem-62-2-357.
3
Immunotherapy for Graves' ophthalmopathy.格雷夫斯眼病的免疫疗法。
Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):409-14. doi: 10.1097/MED.0000000000000097.
4
Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.促甲状腺素受体抗体与Graves眼病临床特征的关联
Clin Endocrinol (Oxf). 2000 Mar;52(3):267-71. doi: 10.1046/j.1365-2265.2000.00959.x.
5
Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy.格雷夫斯眼病中针对人眼肌细胞的免疫介导细胞毒性作用。
J Clin Endocrinol Metab. 1986 Aug;63(2):316-22. doi: 10.1210/jcem-63-2-316.
6
Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.Graves 眼病活动期和中重度患者的治疗进展。
Lancet Diabetes Endocrinol. 2017 Feb;5(2):134-142. doi: 10.1016/S2213-8587(16)30046-8. Epub 2016 Jun 23.
7
Correlation of orbital muscle changes evaluated by magnetic resonance imaging and thyroid-stimulating antibody in patients with Graves' ophthalmopathy.格雷夫斯眼病患者眼眶肌肉变化的磁共振成像评估与促甲状腺素抗体的相关性
Acta Endocrinol (Copenh). 1993 Sep;129(3):213-9. doi: 10.1530/acta.0.1290213.
8
Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.甲状腺功能亢进性格雷夫斯眼病中神经生长因子水平降低，凸显了神经保护因子在自身免疫性甲状腺疾病中的作用。
Cytokine. 2006 Aug;35(3-4):109-14. doi: 10.1016/j.cyto.2006.08.002. Epub 2006 Sep 27.
9
Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.新型甲状腺与眼肌共享蛋白G2s的克隆与特性分析：针对G2s的自身抗体与格雷夫斯甲状腺功能亢进症患者的眼病密切相关。
J Clin Endocrinol Metab. 2000 Apr;85(4):1641-7. doi: 10.1210/jcem.85.4.6553.
10
Antithyroglobulin monoclonal and autoantibodies cross-react with an orbital connective tissue membrane antigen: a possible mechanism for the association of ophthalmopathy with autoimmune thyroid disorders.抗甲状腺球蛋白单克隆抗体和自身抗体与眼眶结缔组织膜抗原发生交叉反应：这可能是眼病与自身免疫性甲状腺疾病相关联的一种机制。
Clin Exp Immunol. 1985 Nov;62(2):361-70.
引用本文的文献
1
Cytokines in Thyroid-Associated Ophthalmopathy.甲状腺相关眼病中的细胞因子。
J Immunol Res. 2022 Nov 14;2022:2528046. doi: 10.1155/2022/2528046. eCollection 2022.
2
Autoantibodies - enemies, and/or potential allies?自身抗体——敌人，还是潜在的盟友？
Front Immunol. 2022 Oct 19;13:953726. doi: 10.3389/fimmu.2022.953726. eCollection 2022.
3
Thyroid Eye Disease: Navigating the New Treatment Landscape.甲状腺眼病：探索新的治疗前景
J Endocr Soc. 2021 Mar 17;5(5):bvab034. doi: 10.1210/jendso/bvab034. eCollection 2021 May 1.
4
Below the Surface: IGF-1R Therapeutic Targeting and Its Endocytic Journey.深入剖析：IGF-1R 治疗靶点及其内吞途径。
Cells. 2019 Oct 9;8(10):1223. doi: 10.3390/cells8101223.
本文引用的文献
1
Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.胰岛素样生长因子-I受体与甲状腺相关性眼病
Endocr Rev. 2019 Feb 1;40(1):236-267. doi: 10.1210/er.2018-00066.
2
Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial.托珠单抗治疗中重度糖皮质激素抵抗性格雷夫斯眼病患者的疗效：一项随机临床试验。
Am J Ophthalmol. 2018 Nov;195:181-190. doi: 10.1016/j.ajo.2018.07.038. Epub 2018 Aug 4.
3
Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.在类风湿关节炎和银屑病试验中，原研 TNF 抑制剂和生物类似药的疗效和安全性结局：系统文献回顾。
BioDrugs. 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4.
4
Slit2 Modulates the Inflammatory Phenotype of Orbit-Infiltrating Fibrocytes in Graves' Disease.Slit2 调节格雷夫斯病眼眶浸润成纤维细胞的炎症表型。
J Immunol. 2018 Jun 15;200(12):3942-3949. doi: 10.4049/jimmunol.1800259. Epub 2018 May 11.
5
Teprotumumab for Thyroid-Associated Ophthalmopathy.替普罗单抗治疗甲状腺相关性眼病
N Engl J Med. 2017 May 4;376(18):1748-1761. doi: 10.1056/NEJMoa1614949.
6
Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy.胰岛素样生长因子-1受体抑制剂（甘尼单抗、达洛珠单抗、西妥昔单抗、替普洛单抗和费格司他单抗）对癌症治疗作用的最新进展。
Oncotarget. 2017 Apr 25;8(17):29501-29518. doi: 10.18632/oncotarget.15704.
7
Graves' Disease.格雷夫斯病
N Engl J Med. 2016 Oct 20;375(16):1552-1565. doi: 10.1056/NEJMra1510030.
8
Efficacy of rituximab in refractory neuromyelitis optica.利妥昔单抗治疗难治性视神经脊髓炎的疗效
Mult Scler. 2016 Jun;22(7):955-9. doi: 10.1177/1352458515602337. Epub 2015 Sep 11.
9
Mechanisms of Action of TSHR Autoantibodies.促甲状腺激素受体自身抗体的作用机制
Horm Metab Res. 2015 Sep;47(10):735-52. doi: 10.1055/s-0035-1559648. Epub 2015 Sep 11.
10
Pentraxin-3 Is a TSH-Inducible Protein in Human Fibrocytes and Orbital Fibroblasts.五聚素3是人类成纤维细胞和眼眶成纤维细胞中一种促甲状腺激素诱导蛋白。
Endocrinology. 2015 Nov;156(11):4336-44. doi: 10.1210/en.2015-1399. Epub 2015 Aug 19.
Zotero 插件